Key Takeaways Moderna shares surged Tuesday after Canadian regulators approved the biotech firm's updated COVID-19 vaccine. Moderna's Spikevax KP.2 targets the KP.2 variant of the virus. The U.S. Food and Drug Administration has also approved the shot, as well as updated vaccines from Pfizer and BioNTech. Moderna (MRNA) shares surged Tuesday after Canadian regulators approved the biotech firm's updated COVID-19 vaccine. The company reported Health Canada authorized the use of its Spikevax KP.2 shot for thos ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Moderna To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Moderna between January 18, 2023 and June 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 17, 2024 /PRNews ...

Moderna (MRNA) closed the most recent trading day at $69.17, moving +1.3% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.13%. On the other hand, the Dow registered a gain of 0.55%, and the technology-centric Nasdaq decreased by 0.52%. Heading into today, shares of the biotechnology company had lost 21.37% over the past month, lagging the Medical sector's gain of 3.34% and the S&P 500's gain of 3.67% in that time. Market participants will be closely following the financia ...

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Moderna investors who were adversely affected by alleged securities fraud between January 18, 2023 and June 25, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moderna-lawsuit-submission-for ...

Moderna Today MRNA Moderna $68.94 +0.66 (+0.97%) 52-Week Range $62.55 ▼ $170.47 Price Target $108.53 Add to Watchlist Moderna Inc. NASDAQ: MRNA made headlines during the pandemic for its messenger ribonucleic acid (mRNA) technology used in its COVID-19 vaccine Spikevax. mRNA vaccines deliver a virus's blueprints or genetic instructions to the cells to trigger the immune system to make antibodies to protect against it. MRNA stock peaked at $497.40 on Aug. 9, 2021, as its COVID-19 vaccines generated over $36 ...

NEW YORK, Sept. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=102401&from=4 CLASS PERIOD: January 18, 2023 to June 2 ...

This highflier has fallen on hard times recently. Moderna Therapeutics (MRNA -2.01%) was once the darling of the healthcare space for investors. The company emerged as one of the biggest names of the COVID-19 pandemic with its vaccine. While COVID has not gone away, the virus is no longer top of mind, and fewer people feel the need to update their vaccination for the illness. With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its 2024 Inv ...

Moderna held its annual R&D day this week. Moderna's (MRNA -2.01%) struggles may last a little longer than expected. The biotech company had seen both sales and its stock price plummet as demand for its coronavirus vaccine waned, but seemed to be on the road to recovery. It won approval for its new respiratory syncytial virus (RSV) vaccine, reported positive data from trials of late-stage candidates, and even saw its shares climb about 20% in the first half of the year. But Moderna's news hasn't been as bri ...

Key Takeaways Shares of Moderna fell Friday after taking on steep losses a day earlier on the news that it plans to cut research and development spending by $1.1 billion by 2027. JP Morgan analysts, meanwhile lowered their rating to underperform from neutral. JP Morgan's $70 price target on the stock is substantially below Wall Street's consensus of around $100. Shares of Moderna (MRNA) fell for the second day in a row after the company said it would slash its research and development expenditures. The stoc ...

At its annual R&D Day, Moderna (MRNA) announcedseveral updates about the advancements in its pipeline and its business outlook for the next four years. MRNA to Cut R&D Costs, Stops Five Pipeline Programs Management implemented a portfolio prioritization and cost efficiencies program to reduce annual research and development (R&D) expenses and focus on products that are either nearing approvals or already on the market. The firm reduced its overall R&D budget for the next four years (2025 to 2028) by nearly ...